ArticleArchives of medical sciences. Atherosclerotic diseases2023
Liver injury in COVID-19 patients with non-alcoholic fatty liver disease: an update.
Article in Archives of medical sciences. Atherosclerotic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Impact of non-alcoholic fatty liver disease on coronavirus disease 2019: A systematic review.World journal of hepatology · 2024Article
- Retrospective study about clinical severity and epidemiological analysis of the COVID-19 Omicron subvariant lineage-infected patients in Hohhot, China.BMC infectious diseases · 2024Article
- Molecular mechanisms underlying SARS-CoV-2 hepatotropism and liver damage.World journal of hepatology · 2024Article
- Role of Perturbated Hemostasis in MASLD and Its Correlation with Adipokines.Life (Basel, Switzerland) · 2024Review
- COVID-19 + Cirrhosis = Excess Hospital Confinement, Excess Casualties.Digestive diseases and sciences · 2023Article
- Liver Damage and Impaired Coagulation in COVID-19 Patients: A Case Series.Diseases (Basel, Switzerland) · 2023Article
- COVID-19 and the Liver: A Complex and Evolving Picture.Hepatic medicine : evidence and research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has revolutionized the priorities of the medical society worldwide. Although most patients infected with SARS-CoV-2 exhibit respiratory symptoms, other organs may also be involved, including the liver, often resulting in liver injury. Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, and its prevalence is expected to increase together with the epidemics of type 2 diabetes and obesity. Data about liver injury during COVID-19 are numerous, while overviews of this infection in patients with NAFLD, both in terms of respiratory and liver, are emerging. In this review, we summarise the current research focusing on COVID-19 in NAFLD patients and discuss the association between liver injury in COVID-19 subjects and non-alcoholic fatty liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.